Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
93% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ROSG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ROSG' s Cash to Debt Range Over the Past 10 Years
Min: 2.76  Med: 139.78 Max: No Debt
Current: No Debt
Equity to Asset 0.85
ROSG's Equity to Asset is ranked higher than
84% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ROSG: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
ROSG' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.85 Max: 0.95
Current: 0.85
0.33
0.95
Interest Coverage No Debt
ROSG's Interest Coverage is ranked higher than
87% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. ROSG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ROSG' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -8.29
M-Score: -32.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -294.91
ROSG's Operating margin (%) is ranked lower than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. ROSG: -294.91 )
Ranked among companies with meaningful Operating margin (%) only.
ROSG' s Operating margin (%) Range Over the Past 10 Years
Min: -9864.67  Med: -4550.20 Max: -1074
Current: -294.91
-9864.67
-1074
Net-margin (%) -293.55
ROSG's Net-margin (%) is ranked lower than
82% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. ROSG: -293.55 )
Ranked among companies with meaningful Net-margin (%) only.
ROSG' s Net-margin (%) Range Over the Past 10 Years
Min: -11003.33  Med: -5245.51 Max: -1094.65
Current: -293.55
-11003.33
-1094.65
ROE (%) -36.63
ROSG's ROE (%) is ranked lower than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. ROSG: -36.63 )
Ranked among companies with meaningful ROE (%) only.
ROSG' s ROE (%) Range Over the Past 10 Years
Min: -545.27  Med: -79.78 Max: -47.3
Current: -36.63
-545.27
-47.3
ROA (%) -32.22
ROSG's ROA (%) is ranked lower than
69% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. ROSG: -32.22 )
Ranked among companies with meaningful ROA (%) only.
ROSG' s ROA (%) Range Over the Past 10 Years
Min: -240.7  Med: -78.20 Max: -40.87
Current: -32.22
-240.7
-40.87
ROC (Joel Greenblatt) (%) -60.99
ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. ROSG: -60.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ROSG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3022.16  Med: -1067.47 Max: -199.41
Current: -60.99
-3022.16
-199.41
Revenue Growth (3Y)(%) -15.70
ROSG's Revenue Growth (3Y)(%) is ranked lower than
82% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. ROSG: -15.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ROSG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -15.7
Current: -15.7
EBITDA Growth (3Y)(%) -55.00
ROSG's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. ROSG: -55.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ROSG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.7  Med: -35.65 Max: -4.6
Current: -55
-68.7
-4.6
EPS Growth (3Y)(%) -55.40
ROSG's EPS Growth (3Y)(%) is ranked lower than
94% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ROSG: -55.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ROSG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.9  Med: -31.45 Max: 3.4
Current: -55.4
-68.9
3.4
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.55
ROSG's P/B is ranked higher than
93% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ROSG: 0.55 )
Ranked among companies with meaningful P/B only.
ROSG' s P/B Range Over the Past 10 Years
Min: 0.55  Med: 1.78 Max: 4.84
Current: 0.55
0.55
4.84
P/S 2.06
ROSG's P/S is ranked higher than
55% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ROSG: 2.06 )
Ranked among companies with meaningful P/S only.
ROSG' s P/S Range Over the Past 10 Years
Min: 2.05  Med: 55.85 Max: 209.09
Current: 2.06
2.05
209.09
Current Ratio 5.57
ROSG's Current Ratio is ranked higher than
77% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ROSG: 5.57 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 7.67 Max: 26.26
Current: 5.57
0.65
26.26
Quick Ratio 5.57
ROSG's Quick Ratio is ranked higher than
78% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ROSG: 5.57 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 7.67 Max: 26.26
Current: 5.57
0.65
26.26
Days Sales Outstanding 803.71
ROSG's Days Sales Outstanding is ranked lower than
100% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. ROSG: 803.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.98  Med: 126.39 Max: 885.73
Current: 803.71
38.98
885.73
Days Payable 219.90
ROSG's Days Payable is ranked higher than
88% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. ROSG: 219.90 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 156.87  Med: 663.73 Max: 1066.71
Current: 219.9
156.87
1066.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.89
ROSG's Price/Net Cash is ranked higher than
85% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.81 vs. ROSG: 8.89 )
Ranked among companies with meaningful Price/Net Cash only.
ROSG' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 4.50 Max: 37.67
Current: 8.89
1.31
37.67
Price/Net Current Asset Value 0.73
ROSG's Price/Net Current Asset Value is ranked higher than
94% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. ROSG: 0.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ROSG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.14  Med: 3.08 Max: 9.53
Current: 0.73
1.14
9.53
Price/Tangible Book 0.58
ROSG's Price/Tangible Book is ranked higher than
93% of the 218 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. ROSG: 0.58 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.47 Max: 7.69
Current: 0.58
0.88
7.69
Price/Median PS Value 0.12
ROSG's Price/Median PS Value is ranked higher than
95% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ROSG: 0.12 )
Ranked among companies with meaningful Price/Median PS Value only.
ROSG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.48 Max: 14.45
Current: 0.12
0.24
14.45
Earnings Yield (Greenblatt) (%) -200.47
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ROSG: -200.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -205.68  Med: 70.80 Max: 2708.8
Current: -200.47
-205.68
2708.8

More Statistics

Revenue(Mil) $5
EPS $ -1.39
Beta0.74
Short Percentage of Float5.46%
52-Week Range $0.71 - 5.55
Shares Outstanding(Mil)14.84

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 10 18 27 35
EPS($) -0.98 -0.68 -0.21 -0.05
EPS without NRI($) -0.98 -0.68 -0.21 -0.05

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference Feb 08 2016
Rosetta Genomics Announces Agreement with America’s Choice Provider Network for Entire Suite of... Feb 01 2016
Rosetta Genomics Announces Agreement with America’s Choice Provider Network for Entire Suite of... Feb 01 2016
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for... Jan 25 2016
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for... Jan 25 2016
Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of... Jan 11 2016
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules... Jan 11 2016
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the... Jan 06 2016
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the... Jan 06 2016
Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating Dec 18 2015
4 Stocks Under $10 Showing Great Upside Today Dec 18 2015
4 Biotech Stocks Under $10 Poised for Big Breakouts Dec 18 2015
Coverage initiated on Rosetta Genomics by Cantor Fitzgerald Dec 18 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics to Present at the LD Micro Main Event Dec 09 2015
Rosetta Genomics Reports Third Quarter 2015 Financial Results Dec 09 2015
ROSETTA GENOMICS LTD. Financials Dec 08 2015
ROSG Reports Record Revenue for Third Quarter 2015 Dec 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK